Company: SHPH
Filing Date: 2025-04-10
Form Type: PRER14A
Source: 0001641172-25-003635
Chunk: 5

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-10
Form: PRER14A
Chunk 5
---
 and its stockholders.

PROPOSAL NO. 5: APPROVAL OF THE FIRST AMENDMENT TO THE SHUTTLE PHARMACEUTICALS HOLDINGS, INC. 2018 EQUITY INCENTIVE PLAN TO INCREASE THE AMOUNT OF SHARES RESERVED FOR ISSUANCE BY 5,000,000 SHARES OF COMMON STOCK.

The Board of Directors recommends that
you vote FOR the first amendment to the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan to increase the amount of shares
reserved for issuance by 5,000,000 shares of common stock. We believe that increase the number of shares reserved under the Company’s
2018 Equity Incentive Plan is in the best interest of the Company and its stockholders.

PROPOSAL NO. 6: APPROVAL OF THE ISSUANCE OF MORE THAN 19.99% OF OUR COMMON STOCK UPON CONVERSION OF THE OCTOBER 2024 CONVERTIBLE NOTES IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(D).

The Board of Directors recommends that you vote
FOR the issuance of more than 19.99% of our common stock upon conversion of convertible notes issued to investors in the October 2024
private placement, in compliance with Nasdaq Listing Rule 5635(d). We believe the approval of the issuance in excess of 19.99% of our
common stock upon conversion of the October 2024 convertible notes will be of benefit to the Company and its stockholders as converting
the Convertible Notes will allow us to preserve cash and apply any cash that would have been paid toward satisfying the convertible notes
can instead be applied toward our ongoing Phase 2 clinical trial of Ropidoxuridine.

| 3 |

introduction to our Board of Directors

|                                       |     |     |     |              |     | Committee   
 Memberships |     |              |     |            |
| Name                                  
 and Position                          |     | Age |     | Other        
 Public Board 
 Memberships  |     | Audit       |     | Compensation |     | Nominating 
 &          
 Corporate  
 Governance |
| ANATOLY                               
 DRITSCHILO, MD                        
 CHIEF SCIENTIFIC OFFICER AND CHAIRMAN |     |  80 |     |              |     |             |     |              |     |            |
| STEVEN                                
 RICHARDS                              
 INDEPENDENT                           
 DIRECTOR                              |     |  56 |